

Scott D Berkowitz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6906787/scott-d-berkowitz-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

166
papers

21,617
citations

57
h-index

146
g-index

183
ext. papers

25,676
ext. citations

10.3
avg, IF

6.03
L-index

#	Paper	IF	Citations
166	Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD.. <i>Vascular Medicine</i> , 2022 , 1358863X221085606	3.3	2
165	Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. <i>International Journal of Stroke</i> , 2021 , 17474930211058012	6.3	1
164	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021 , 144, 1831-1841	16.7	4
163	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1768-1778	15.1	3
162	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 21-29	16.2	12
161	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021 , 107, 1130-1137	5.1	0
160	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021 , 236, 4-12	4.9	1
159	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. <i>Heart Rhythm O2</i> , 2021 , 2, 215-222	2.2	1
158	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 317-326	15.1	6
157	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021 , 117, 942-949	9.9	7
156	Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 11-20	17.2	5
155	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 511-525	15.1	3
154	Regional, sex, and age differences in diagnostic testing among participants in the NAVIGATE-ESUS trial. <i>International Journal of Stroke</i> , 2021 , 16, 55-62	6.3	1
153	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 14-23	15.1	9
152	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021 , 144, 1104-1116	16.7	2
151	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021 , 331, 38-44	3.1	
150	Risk stratification of cardiovascular complications using CHADS-VASc and CHADS scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021 , 337, 9-15	3.2	0

149	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 757-759	15.1	1
148	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. <i>European Heart Journal</i> , 2021 , 42, 4040-4048	8.5	3
147	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. <i>Stroke</i> , 2021 , STROKEAHA120032976	6.7	0
146	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021 , 10, e022485	6	
145	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. <i>Circulation</i> , 2020 , 142, 2219-2230	16.7	17
144	Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020 , 51, 2139-2147	6.7	2
143	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020 , 141, 1141-1151	16.7	21
142	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020 , 382, 1994-2004	59.2	248
141	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <i>Circulation</i> , 2020 , 141, 1841-1854	16.7	53
140	High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020 , 51, 2386-2394	6.7	11
139	Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. <i>European Journal of Neurology</i> , 2020 , 27, 841-848	6	7
138	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 130-139	27.4	54
137	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1672-1685	15.4	20
136	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 1-11	5.1	3
135	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 20-29	5.1	7
134	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 50, 12-19	5.1	3
133	Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2020 , 142,	16.7	1
132	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020 , 4, 6250-6258	7.8	11

131	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020 , 7, e18-e27	14.6	74
130	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020 , 51, 938-943	6.7	19
129	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020 , 4, 4632-4639	7.8	10
128	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020 , 29, 104936	2.8	8
127	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 , 77, 1233-1240	17.2	11
126	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , 2020 , 51, 2901-2909	6.7	5
125	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 296-307	3.9	17
124	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020 , 51, 1797-1804	6.7	18
123	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019 , 40, 3771-3778a	9.5	19
122	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019 , 140, 1451-1459	16.7	22
121	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. <i>Stroke</i> , 2019 , 50, 3184-3190	6.7	39
120	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1519-1528	15.1	17
119	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019 , 139, 1134-1145	16.7	72
118	Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS. <i>International Journal of Stroke</i> , 2019 , 14, 915-922	6.3	10
117	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019 , 28, 2273-2279	2.8	15
116	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial. <i>JAMA Neurology</i> , 2019 , 76, 764-773	17.2	79
115	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , 2019 , 14, 270-281	6.3	9
114	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019 , 50, 2477-2485	6.7	47

113	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019 , 13, 1753944719863641	3.4	3
112	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019 , 8, 283-295	2.8	
111	Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 805-814	4.5	6
110	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019 , 5, 145-152	4.6	43
109	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018 , 257, 78-83	3.2	7
108	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018 , 200, 102-109	4.9	5
107	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. <i>Clinical Cardiology</i> , 2018 , 41, 39-45	3.3	9
106	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018 , 199, 83-91	4.9	71
105	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018 , 27, 1673-1682	2.8	37
104	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018 , 199, 59-67	4.9	15
103	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	4.0	204
102	Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis. <i>Thrombosis Journal</i> , 2018 , 16, 29	5.6	10
101	Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. <i>Thrombosis Journal</i> , 2018 , 16, 34	5.6	15
100	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. <i>Lancet Neurology, The</i> , 2018 , 17, 1053-1060	24.1	99
99	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2018 , 7, e008755	6	10
98	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <i>Blood Advances</i> , 2018 , 2, 3193-3195	7.8	
97	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. <i>New England Journal of Medicine</i> , 2018 , 378, 2191-2201	59.2	432
96	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. <i>Circulation</i> , 2017 , 135, 1001-1009	16.7	18

95	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. <i>Thrombosis Research</i> , 2017 , 156, 184-190	8.2	7
94	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4
93	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017 , 120, 588-594	3	26
92	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). <i>American Journal of Cardiology</i> , 2017 , 119, 1989-1996	3	61
91	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2017 , 376, 1211-1222	59.2	397
90	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
89	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). <i>American Journal of Cardiology</i> , 2017 , 120, 1837-1840	3	9
88	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1694-702	5	19
87	Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. <i>American Heart Journal</i> , 2016 , 178, 74-84	4.9	32
86	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016 , 179, 77-86	4.9	42
85	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. <i>Circulation</i> , 2016 , 134, 37-47	16.7	93
84	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016 , 102, 1036-43	5.1	30
83	Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 412-22	3.3	21
82	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016 , 5, e002197	6	94
81	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016 , 133, 352-60	16.7	102
80	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016 , 1, 146-154	5.6	65
79	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". <i>Circulation</i> , 2016 , 134, e7-8	16.7	1
78	Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016 , 11, 526-33	6.3	86

77	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. <i>Europace</i> , 2016 , 18, 1135-42	18
76	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015 , 170, 675-682.e8	4.9 90
75	Cardiovascular drug development: is it dead or just hibernating?. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1567-82	15.1 104
74	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet, The</i> , 2015 , 385, 2363-70	4.0 100
73	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2271-2281	15.1 127
72	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. <i>European Heart Journal</i> , 2015 , 36, 288-96	9.5 203
71	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015 , 169, 751-7	4.9 62
70	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014 , 35, 1873-80	9.5 126
69	Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. <i>Stroke</i> , 2014 , 45, 1304-12	6.7 151
68	Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2041-2048	15.1 172
67	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. <i>Lancet Haematology, the</i> , 2014 , 1, e37-46	14.6 186
66	Allogeneic blood transfusions and postoperative infections after total hip or knee arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2014 , 96, 272-8	5.6 161
65	Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial. <i>Stroke</i> , 2014 , 45, 1739-47	6.7 106
64	Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. <i>Vascular Health and Risk Management</i> , 2014 , 10, 157-67	4.4 20
63	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014 , 35, 3377-85	9.5 127
62	Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1428-36	15.4 155
61	Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. <i>Journal of the American Heart Association</i> , 2014 , 3, e000521	6.1 80
60	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014 , 11, 925-32	6.7 43

59	Complication rates after hip or knee arthroplasty in morbidly obese patients. <i>Clinical Orthopaedics and Related Research</i> , 2013 , 471, 3358-66	2.2	127
58	Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2013 , 61, 651-8	15.1	159
57	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , 2013 , 34, 1621-9	9.5	8
56	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. <i>Thrombosis Journal</i> , 2013 , 11, 21	5.6	378
55	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <i>International Journal of Cardiology</i> , 2013 , 167, 1772-82	3.2	53
54	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. <i>Annals of the New York Academy of Sciences</i> , 2013 , 1291, 42-55	6.5	16
53	Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin). <i>Acta Anaesthesiologica Scandinavica</i> , 2013 , 57, 565-72	1.9	27
52	Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. <i>Circulation: Heart Failure</i> , 2013 , 6, 740-7	7.6	82
51	End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013 , 6, 470-8	5.8	30
50	Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. <i>Annals of Internal Medicine</i> , 2013 , 158, 861-8	8	39
49	The discovery of rivaroxaban: translating preclinical assessments into clinical practice. <i>Frontiers in Pharmacology</i> , 2013 , 4, 145	5.6	13
48	The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012 , 94, 1573-8		36
47	Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>New England Journal of Medicine</i> , 2012 , 366, 1287-97	59.2	1692
46	Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 883-91	59.2	6302
45	Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. <i>Drug Safety</i> , 2011 , 34, 243-52	5.1	82
44	Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 444-53	7	211
43	The discovery and development of rivaroxaban. <i>Annals of the New York Academy of Sciences</i> , 2011 , 1222, 64-75	6.5	21
42	Oral rivaroxaban for symptomatic venous thromboembolism. <i>New England Journal of Medicine</i> , 2010 , 363, 2499-510	59.2	2240

41	Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. <i>Lancet, The</i> , 2009 , 373, 1673-80	4.0	767
40	Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. <i>Blood</i> , 2008 , 112, 35-35	2.2	5
39	Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery. <i>Blood</i> , 2008 , 112, 436-436	2.2	5
38	Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005 , 87, 2169-77	5.6	40
37	Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 681-9	27.4	229
36	ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005 , 87, 2169-2177	5.6	21
35	Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.. <i>Blood</i> , 2004 , 104, 1771-1771	2.2	
34	Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. <i>New England Journal of Medicine</i> , 2003 , 349, 1703-12	59.2	272
33	Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 1914-94	15.4	38
32	Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 2119-30	15.4	126
31	The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. <i>Journal of Thrombosis and Thrombolysis</i> , 2002 , 14, 91-101	5.1	26
30	Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. <i>Annals of Internal Medicine</i> , 2002 , 137, 648-55	8	159
29	Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. <i>American Heart Journal</i> , 2002 , 144, 73-80	4.9	27
28	Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. <i>American Heart Journal</i> , 2002 , 144, 151-8	4.9	33
27	Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). <i>American Journal of Cardiology</i> , 2001 , 88, 541-6	3	18
26	Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001 , 88, 1230-4	3	31
25	Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. <i>Circulation</i> , 2001 , 103, 1838-43	16.7	575
24	Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. <i>Archives of Internal Medicine</i> , 2001 , 161, 2215-21		130

23	New heparin dosing recommendations for patients with acute coronary syndromes. <i>American Journal of Medicine</i> , 2001 , 110, 641-50	2.4	25
22	Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. <i>American Heart Journal</i> , 2001 , 141, 226-33	4.9	62
21	Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies. <i>American Heart Journal</i> , 2001 , 142, 7-13	4.9	9
20	Efficacy of abciximab readministration in coronary intervention. <i>American Journal of Cardiology</i> , 2000 , 85, 435-40	3	42
19	Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. <i>American Heart Journal</i> , 2000 , 140, 74-80	4.9	75
18	Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000 , 30 Suppl 3, 27-43		2
17	Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. <i>Circulation</i> , 1999 , 99, 2892-900	16.7	127
16	Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. <i>American Heart Journal</i> , 1999 , 138, 317-26	4.9	51
15	Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. <i>Current Opinion in Hematology</i> , 1999 , 6, 334-41	3.3	22
14	Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatid. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1518-24	15.1	75
13	Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. <i>Journal of the American College of Cardiology</i> , 1998 , 32, 311-9	15.1	129
12	Progress in point-of-care laboratory testing for assessing platelet function. <i>American Heart Journal</i> , 1998 , 136, S51-65	4.9	13
11	Relation between inhibition of platelet aggregation and clinical outcomes. <i>American Heart Journal</i> , 1998 , 136, S43-50	4.9	20
10	Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q wave myocardial infarction]. <i>Circulation</i> , 1998 , 97, 1702-7	16.7	147
9	Glycoprotein IIb/IIIa integrin blockade. <i>Circulation</i> , 1998 , 98, 2629-35	16.7	105
8	Hemodilution with other blood reinfusion techniques in total hip arthroplasty. <i>Clinical Orthopaedics and Related Research</i> , 1997 , 132-9	2.2	31
7	Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1997 , 11, 875-7	2.1	12
6	Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. <i>Circulation</i> , 1997 , 95, 2508-16	16.7	143

5	Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. <i>Circulation</i> , 1997 , 95, 809-13	16.7	168
4	Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study. <i>Thrombosis and Haemostasis</i> , 1997 , 77, 032-038	7	85
3	Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 360	15.1	2
2	Analysis of the occurrence and clinical significance of thrombocytopenis with c7E3 (abciximab) in the EPIC trial. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 82	15.1	2
1	Thrombin and fibrin activity in patients treated with enoxaparin, ticlopidine and aspirin versus the conventional coumadin regimen after elective stenting: The ENTICES trial. <i>Journal of the American College of Cardiology</i> , 1996 , 27, 334	15.1	3